IGHV1-2*04 Heavy Chain Dominance Drives Autoreactivity in SMZL | Blood Cancers Today
An MZL subgroup appears to exhibit diverse complementarity-determining region 3 characteristics, pronounced intraclonal diversification, and heavy chain dominance
Related Articles
Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets
Ellrott et al. provide a means to assign patient samples from clinical trials and other cancer genome studies to published TCGA molecular subtypes. Applying machine learning…
OCE Conversations on Cancer – Cervical Cancer Treatment Innovation: A Collaborative Discussion
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Prior authorisation is can harm patients with cancer in the USA
In the USA, before a patient can receive certain treatments or medications, a prior authorisation from their health insurance company is needed. A new USA-wide…
2024 Most Read Articles | Blood Advances | American Society of Hematology
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
Cellular Cancer Biology Imaging Research
The Cellular Cancer Biology Imaging Research (CCBIR) Centers are developing and testing enabling imaging technologies at the cellular and organ scales driven by specific fundamental…
AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals
Overview for AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals
Phase 3 Trial to Explore Ivosidenib for IDH1-Mutated MDS | Blood Cancers Today
A study aim to expand treatment options for patients with IDH1-mutant MDS, a challenging subset of patients characterized by poor prognosis.
2024 Most Read Articles | Blood Advances | American Society of Hematology
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
A Phase I study of CLAG-M and lintuzumab-Ac225 in high-risk R/R AML
Sameem Abedin, MD, Medical College of Wisconsin, Milwaukee, WI, discusses a Phase I study investigating CLAG-M salvage chemotherapy and lintuzumab-Ac225, a radio-labeled antibody against CD33,…
Welcome! You are invited to join a webinar: Skin VJSessions: Therapeutic Advances in PD-1 Refractory Skin Cancer. After registering, you will receive a confirmation email about joining the webinar.
Therapeutic options for PD-1 refractory skin cancer 3 Jan – 6PM BST | 1PM EDT | 10AM PDT Allison Betof Warner, Omid Hamid, Inderjit Mehmi…
